E-QURE's BST Device for Chronic Wound Care Receives Marketing Approval in Israel

Monday, February 27, 2017

E-QURE Corp., a leader in medical devices for the treatment of advanced wound care, announced today it has received marketing approval for the Company's patented Bio-electrical Signal Therapy Device ("BST Device") in Israel from the Israeli Ministry of Health. The Accessories and Medical Devices Registration (AMAR) is granted in order to secure safety and efficacy for medical devices used in Israel. BST is a breakthrough novel electrotherapy for the non-invasive treatment of hard-to-heal chronic wounds.

E-QURE intends to immediately begin marketing efforts in Israel by activating its signed distribution agreement with Chemipal Ltd, which was concluded last year and was pending AMAR approval. The Israeli advanced wound care market size is estimated at $250 million, with no electrical device on the market prior to the BST's approval.

E-QURE intends to start commercial activity in the private healthcare market, and has filed for including BST treatment in Israel's approved National Health Basket, the national healthcare reimbursement system.

"Israel is going to be our commercial pilot sales market. Taking advantage of this small but lucrative wound care market, we intend to build revenues and implement sales techniques that will help us in other markets around the world," stated Ron Weissberg, Chairman of E-QURE Corp.